Enasidenib (ENA) Monotherapy with Addition of Azacitidine in Non-Responders Is Effective in Older Patients with Newly Diagnosed IDH2 Mutated Acute Myeloid Leukemia (AML): A Completed Phase 2/1b Sub-Study of the Beat AML Master Trial
Year: 2020
Type: article
Study design: Clinical Trial
Source: Blood
Authors: Eytan M. Stein, Ying Huang, Uma Borate, Maria R. Baer, Wendy Stock, Tibor Kovacsovics, William Blum, Gary J. Schiller, Rebecca L. Olin, James M. Foran, Mark Litzow, Tara Lin, Prapti A. Patel, Matthew C Foster, Michael Boyiadzis, Robert H. Collins, Jo-Anne Vergilio, Nyla A Heerema, Leonard Rosenberg, Ashley Owen Yocum, Timothy Chen, Franchesca Druggan, Sonja Marcus, Mona Stefanos, Jordan Chervin, Abigail Shoben, Brian J. Druker, Amy Burd, John C. Byrd, Ross L. Levine, Alice S. Mims
Institutions: Memorial Sloan Kettering Cancer Center, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Oregon Health & Science University, University of Maryland, Baltimore, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Chicago Medical Center, University of Utah, Huntsman Cancer Institute, Emory University, University of California, Los Angeles, University of California, San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center, Mayo Clinic in Florida, Mayo Clinic, University of Kansas, The University of Texas Southwestern Medical Center, University of North Carolina at Chapel Hill, UNC Lineberger Comprehensive Cancer Center, UPMC Hillman Cancer Center, Harold C. Simmons Comprehensive Cancer Center, Foundation Medicine (United States), Blood Cancer United, OHSU Knight Cancer Institute
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W3095277123